Anika Therapeutics
ANIK
108 hedge funds and large institutions have $191M invested in Anika Therapeutics in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 42 reducing their positions, and 15 closing their positions.
43% more call options, than puts
Call options by funds: $33K | Put options by funds: $23K
3.88% more ownership
Funds ownership: 85.53% → 89.41% (+3.9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
1% less funds holding
Funds holding: 109 → 108 (-1)
8% less capital invested
Capital invested by funds: $206M → $191M (-$15.5M)
21% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$6.57M |
| 2 |
CSC
Cove Street Capital
El Segundo,
California
|
+$1.25M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.06M |
| 4 |
Millennium Management
New York
|
+$866K |
| 5 |
Cerity Partners
New York
|
+$490K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFA
Alta Fundamental Advisers
New York
|
-$3.82M |
| 2 |
Morgan Stanley
New York
|
-$1.07M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$910K |
| 4 |
JP Morgan Chase
New York
|
-$754K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$722K |
ANIK Hedge Fund Activity: Q1 2025 in Review
108 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2025, worth a combined $191M — down 7.5% from $206M a quarter earlier.
Fund positioning in ANIK was balanced in Q1 2025: 15 funds opened new positions, 15 closed out, 33 added to existing stakes and 42 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $6.57M. The largest seller was Alta Fundamental Advisers, cutting an estimated $3.82M.
- 108 institutional investors held Anika Therapeutics (ANIK) as of Q1 2025, down from 109 in Q4 2024.
- Funds reported $191M of Anika Therapeutics stock for Q1 2025, down 7.5% quarter-over-quarter.
- 15 funds opened new Anika Therapeutics positions in Q1 2025 and 15 closed out, a net change of 0 holders.
- The largest Anika Therapeutics buyer in Q1 2025 was Opaleye Management, an estimated $6.57M added.
- The largest Anika Therapeutics seller in Q1 2025 was Alta Fundamental Advisers, an estimated $3.82M sold.
Based on aggregated 13F filings for Q1 2025.